---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-009766"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:32:59.887325+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Indaptus reports FY2023 loss of $1.83/sh; cash $13.4M; Phase 1 Decoy20 advancing

## Summary
- FY2023 net loss per share $1.83 vs $1.73 in FY2022; cash at Dec 31, 2023 was $13.4M (down from $26.4M).
- Cash runway expected through Q3 2024; excludes $0.3M ATM proceeds in March 2024.
- Positive results from second cohort of Phase 1 Decoy20 trial; initiating multi-dose in solid tumors.
- European patent approved in Jan 2024 for platform technology covering viral infection composition.
- R&D expenses rose 21% YoY to $7.6M driven by Phase 1 trial and pipeline expansion.

## SEC filing metadata
- accession: 0001493152-24-009766
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/0001493152-24-009766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315224009766/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-009766
- JSON: https://secwatch.observer/filing/0001493152-24-009766.json
- Plain text: https://secwatch.observer/filing/0001493152-24-009766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.